Immunotherapy for non-small cell lung cancer treatment
نویسندگان
چکیده
منابع مشابه
Immunotherapy for Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related mortality worldwide, and more than 80% of cases are of non-small cell lung cancer. Although chemotherapy and molecularly targeted therapy may provide some benefit, there is a need for newer therapies for the treatment of patients with advanced NSCLC. Immunotherapy aims to augment the recognition of cancer as foreign, to stimulate immune respons...
متن کاملImmunotherapy and the Treatment of Non–Small Cell Lung Cancer
W ith more than 200,000 cases expected for 2016, lung cancer is the leading cause of cancer death in both men and women, accounting for more than one-quarter of all cancer deaths. “A lot of people don’t realize that lung cancer has a higher mortality than breast, prostate, and colorectal cancers combined,” said Suzanne Walker, CRNP, MSN, AOCN®, BC, of Abramson Center at Penn Presbyterian Medica...
متن کاملImmunotherapy in the treatment of non-small cell lung cancer.
Advances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulato...
متن کاملAdvances in immunotherapy for non-small cell lung cancer.
In most patients, lung cancer presents as advanced disease with metastases to lymph nodes and/or distant organs, and survival is poor. Lung cancer is also a highly immune-suppressing malignancy with numerous methods to evade antitumor immune responses, including deficiencies in antigen processing and presentation, release of immunomodulatory cytokines, and inhibition of T-cell activation. Advan...
متن کامل[Progress in immunotherapy for non-small cell lung cancer].
In recent years, the five-year survival rate of patients with advanced stage non-small cell lung cancer (NSCLC) remains low despite recent advances in surgery, irradiation, chemotherapy, and targeted therapy. Immunotherapy which utilizes the immune system to control and eradicate cancer is a viable treatment approach for malignancy. Immunotherapy in patients with lung cancer has made breakthrou...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Malignant tumours
سال: 2016
ISSN: 2224-5057
DOI: 10.18027/2224-5057-2016-3-17-24